Jay Skyler
Professor · University of Miami/Jackson Health System
Credentials: · · · ·
History
- 1972–1974
Endocrinology, Diabetes, and Metabolism
- 1969–1972
Internal Medicine
1961–1965
Research
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
New England Journal of Medicine · 2019 · 918 citations
Diabetes Care · 2015 · 904 citations
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
New England Journal of Medicine · 2009 · 862 citations
55 papers
- CG
38 papers
38 papers
28 papers
26 papers
- JM
20 papers
14 papers
14 papers · 1 as a fellow
Grants
- 2017–2023
Low-Dose IL-2 in Established T1D
National Institute of Allergy and Infectious Diseases · U01
PI · $1.5M · University of Miami School of Medicine
- 2001–2009
Type 1 Diabetes TrialNet: Support Facilities
National Institute of Diabetes and Digestive and Kidney Diseases · U01
Contact PI · $6.1M · University of Miami School of Medicine
- 1993–2005
Diabetes Prevention Trial-Iddm (Dpt-1)
National Institute of Diabetes and Digestive and Kidney Diseases · U01
Contact PI · $18M · University of Miami School of Medicine
- 1985–1989
Diabetes Mellitus: Pathogenesis and Immune Intervention
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $198.1K · University of Miami School of Medicine
Clinical trials
- 2023–2028
Low-dose IL-2 in Established T1D - The "PROREG" Study
Principal investigator · Withdrawn · Phase 1, Phase 2
Jay S. Skyler
- 2010–2013
Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes
Principal investigator · Terminated · Phase 2, Phase 3
Jaeb Center for Health Research
- 2009–2012
Study chair · Completed · Phase 2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- 2008–2012
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
Study chair · Completed · Phase 2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)